811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Pacira and its subsidiary settled all outstanding claims in patent litigation over EXPAREL with Fresenius Kabi, eVenus and Jiangsu Hengrui. Under the agreement, Pacira will license Fresenius Kabi to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. starting in early 2030, with unlimited generic sales permitted from 2039, both before the July 2, 2044 expiration of the last Orange Book-listed EXPAREL patent. Pacira will also pay the Fresenius Parties $7.0 million, which it said reflects expected savings from avoiding continued litigation costs.
Settlement entered April 7, 2025, covering seven listed patent infringement suits and related actions
Volume-limited generic entry starts in early 2030 at a confidential percentage that begins in the high single digits of U.S. volumes and rises to a maximum in the high thirties
Unlimited generic license begins no earlier than 2039, before the July 2, 2044 patent expiration
Pacira will pay the Fresenius Parties $7.0 million; the full agreement will be filed with the 10-Q for the quarter ending March 31, 2025
Greenbrier reported second-quarter fiscal 2025 results for the quarter ended February 28, 2025, with GAAP diluted EPS of $1.56, up from $1.03 a year earlier, while revenue fell to $762.1 million from $862.7 million. The company cut its fiscal 2025 revenue and delivery guidance, raised its aggregate gross margin guidance, and increased its quarterly dividend 7% to $0.32 per share.
GAAP diluted EPS was $1.56 and core diluted EPS was $1.69, including $0.13 per share of European facility rationalization costs.
FY2025 revenue guidance was lowered to $3.15 billion to $3.35 billion from $3.35 billion to $3.65 billion, and deliveries to 21,500 to 23,500 units from 22,500 to 25,000 units.
FY2025 aggregate gross margin guidance was raised to 17.0% to 17.5% from 16.0% to 16.5%.
The quarterly dividend rises to $0.32 per share, payable May 13, 2025, to holders of record as of April 22, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.